Document is current

Article History

Received: 20 September 2024

Accepted: 25 January 2025

First Online: 18 February 2025

Declarations

:

: P.H.W. was supported by the NCT Heidelberg School of Oncology Fellowship Program. P.H.S. was supported by the Physician Scientist Program of the Medical Faculty from 2021 to 2024, has a grant from Dietmar-Hopp Foundation and is part of NovoCure GmbH Advisory Board outside the submitted work. F.W. received speaker fees from AstraZeneca, Varian Medical Systems and Merck Sharp & Dohme and travel Support for attending meetings from Varian Medical Systems and Micropos Medical. M.T.D. received funding from German Cancer Aid, Uniscientia Foundation and Schwiete Foundation, got paid honoraria by Roche and Thieme and received funding for meeting fees by AstraZeneca and is part of AstraZeneca and Eisai Advisory Board outside of this work. B.C.K. received funding from German Cancer Aid, had contracts with AbbVie, Roche and Gilead, received consulting fees from Takeda and speaking honoraria as well as travel compensation from Servier and Pierre Fabre. J.D. received grants from CRI – The Clinical Research Institue GmbH, View Ray Inc., Accuray International Sàrl, Accuray Incorporated, RaySearch Laboratories AB, Vision RT limited, Merck Serono GmbH, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW- Freiburg Dr. Pychlau GmbH, Nanobiotix A.A. outside the submitted work. J.L. received travel support from Micropos Medical and RaySearch Laboratories. The other authors declare no conflict of interest with respect to the contents of this article.